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Background: As a key link between innate and adaptive immune responses, the interferon (IFN) system is the first
line of defense against viral infection. IFN, and in particular, IFN-α, has been used clinically as an effective therapeutic
agent for viral infections. However, different subtypes of IFN-α demonstrate distinct antiviral activity. Therefore, it is
important to identify IFN-α subtypes with high antiviral activity for the development of genetically engineered
antiviral drugs.
Results: In this study, we cloned the genes for 13 IFN-α subtypes from peripheral blood lymphocytes of the mink.
The homologies of the 13 mink IFN-α genes were 93.6–99.3% and 88.8–98.4% at the nucleotide and amino acid
sequence levels, respectively. In contrast to human and canine IFN-α subtypes, most mink IFN-α subtypes contained
two N-glycosylation sites. We expressed and purified 13 mink IFN-α subtypes in Escherichia coli. The cytopathic
effect inhibition assay showed that all the 13 recombinant mink IFN-α subtypes inhibited the propagation of
vesicular stomatitis virus in WISH cells, with IFN-α2 and IFN-α12 demonstrating the highest activities. Furthermore,
recombinant mink IFN-α2 and IFN-α12 significantly suppressed the propagation of canine distemper virus in Vero
cells, with IFN-α2 demonstrating the highest activity.
Conclusions: We identified the mink IFN-α2 subtype as a promising candidate for the development of effective
antiviral drugs.
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Interferon (IFN) was first identified by Isaacs in 1957
[1]. IFN belongs to the cytokine family of proteins and
has a wide range of physiological functions, such as inhi-
biting viral infection, regulating cell proliferation and
differentiation, and modulating immune responses [2].
The IFN system is one of the first defensive barriers
against viral infection and is an important component of
natural antiviral immunity [3,4].
IFNs are key cytokines with antiviral, antitumor, and
immunomodulatory activities. Based on gene sequences,
chromosome location, and receptor specificity, the
members of the IFN family are classified into I, II, and
III subtypes. Subtype I includes IFN-α, β, ω, ε, κ, δ and ζ* Correspondence: yanxijun@163.com
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unless otherwise stated.[5-8], and type I IFNs have been shown to possess effect-
ive antiviral activity. Type II IFN is also known as im-
mune IFN (IFN-γ) [9]. Interferon-γ, a cytokine produced
by T lymphocytes and natural killer cells, plays a central
role in the modulation of the immune response [10].
The type III interferons are also known as the IFN-λs
and are more related to type I IFNs based on their
amino acid sequence and protein function. However, the
more limited tissue expression of IFN-λ receptors sug-
gests that type III IFNs do not simply recapitulate the
type I IFN antiviral system. They have antiviral effects in
the respiratory tract, gastrointestinal tract, skin mucosa,
epithelial cells, and some tumor cells. Among the IFN
family, IFN-α is one of the major modulators of the de-
fensive system against viral infection in mammals and
has been widely used in the clinic as a therapeutic for
viral infection [11,12]. All IFNs identified in vertebrates
are secreted proteins, with IFN-α being secreted from
virus-infected white blood cells. The human IFN familyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The 13 MiIFN-α subtypes cloned in this study














Zhang et al. BMC Veterinary Research  (2015) 11:42 Page 2 of 8consists of 13 subtypes. Despite differences in their amino
acid sequences, the subtypes of human IFN-α have similar
3D structures and similar physiological and biochemical
characteristics, such as stability and recognition by surface
receptors. Human IFN-α is composed of 166–172 amino
acids and has no glycosylation sites. The average molecu-
lar weight of IFN-α is about 19 kDa. The homology of
amino acids among IFN-αs from different subtypes ranges
from about 75–95% [13]. The IFN-αs can be further
classified into subtypes, which have different biological
functions.
IFN is a conserved molecule that has been found in
humans, mouse, sheep, rabbits, dogs, weasels and other
mammals, as well as in fish, turtles and insects. IFNs
have been used in both human and veterinary medicine,
not only for the treatment of viral infections but also for
cancer. Mink (Neovison vison) is one of the major fur
animals and its health problems have become an import-
ant issue for the fur industry. Infection by the canine
distemper virus, Parvovirus, and Aleutian mink disease
virus among minks has caused serious economic losses
to the fur animal industry [14]. Therefore, there is an
urgent need to develop effective, non-toxic, and environ-
mentally friendly antiviral drugs to control viral infec-
tions in mink. In this study, we cloned and expressed
the genes for 13 IFN-α subtypes in the mink and charac-
terized their antiviral activity.
Results
Analysis of mink IFN-α genes
By reverse transcription polymerase chain reaction
(RT-PCR), we successfully amplified the predicted
564 bp mink IFN-α (MiIFN-α) cDNA. Restriction en-
zyme analysis confirmed that we had correctly sub-
cloned MiIFN-α cDNAs into recombinant plasmids.
DNAStar software analysis demonstrated that the
cDNAs of 13 subtypes of MiIFN-α were 564 bp long
and encoded 187 amino acids. Due to the different
amino acids components, there were slight variations
in molecular weight among the 13 MiIFN-α subtypes.
The GenBank registration number and molecular
weight of the cloned 13 MiIFN-α subtypes are listed in
Table 1.
SignalP 4.1 server software (http://www.CBS.DTU.DK/
Services/SignalP) analysis predicted that the N terminal
23 amino acids represented the signal peptide. The hom-
ologies of 13 MiIFN-α subtypes were 93.6–99.3% and
88.8–98.3% at the nucleotide and amino acid sequence
levels, respectively (Table 2).
Most secreted proteins in eukaryotes are modified on
the amino acid Asn located in the consensus sequence
Asn.Xaa.Ser/Thr (NXS/T) by an N-glycan, a process
known as N-glycosylation [15]. Analysis using NetNGlyc
Server 1.0 (http://www.CBS.DTU.DK/Services/NetNGlyc)predicted that IFN-α1–3 contained one glycosylation site
at 54NYTN57, whereas IFN-α4–13 contained two glycosyl-
ation sites. In addition to the glycosylation site at
54NYTN57, IFN-α4–9 and IFN-α13 contained a glycosyla-
tion site at 101NTTL104, whereas IFN-α10–12 contained a
glycosylation site at 101NMTL104. Further analysis demon-
strated that the number and position of cysteines were not
the same among the 13 subtypes. IFN-α1–3, IFN-α5, IFN-
α7, IFN-α10, IFN-α11 and IFN-α13 contained 8 cysteine
residues at the same positions of 5, 16, 24, 52, 92, 109, 122
and 160. IFN-α4, IFN-α6, IFN-α8, IFN-α9 and IFN-α12
contained only 7 cysteine residues with a cysteine residue
at position 16 replaced by serine (Figure 1). These data
demonstrate the existence of a single nucleotide poly-
morphism (SNP) among MiIFN-α subtypes, in agreement
with previous reports on SNPs of IFN-α in other species
[15,16].
Both mink and ferret belong to Mustelidae. The
homology between IFN-α1–13 and the published
sequences for ferret (GenBank registration number:
EF368207) were 95.0–97.3% and 91.5–94.2% at the
nucleotide and amino acid sequence levels, respect-
ively. The amino acid sequence analysis showed that
fox (EF990625), raccoon (EF543192), and canine
(EF28625) IFN-α each contained only one potential N-
glycosylation site at 101NMTL104, which is the same
site in MiIFN-α10–12. The homologies between mink,
fox, raccoon and canine IFN-α were 79.1–80.9% and
68.8–71.4% at the nucleotide and amino acid sequence
levels, respectively. Nucleotide evolution tree analysis
showed significant differences in the nucleotide se-
quences among the 13 subtypes of MiIFN-α and those
of other species of animals and human IFN-αs
(Figure 2).
Table 2 Homology (%) of amino acids and nucleotides among MiIFN-α subtypes
IFN-α1 IFN-α2 IFN-α3 IFN-α4 IFN-α5 IFN-α6 IFN-α7 IFN-α8 IFN-α9 IFN-α10 IFN-α11 IFN-α12 IFN-α13
IFN-α1 - 99.3 97.0 95.0 96.3 94.5 94.7 94.7 93.8 94.7 94.3 96.1 95.4
IFN-α2 98.4 - 96.6 95.7 97.0 95.2 94.7 94.9 94.0 94.3 94.0 95.7 95.0
IFN-α3 94.7 94.1 - 96.3 96.8 94.7 96.3 96.6 95.7 96.3 95.2 98.0 95.6
IFN-α4 90.4 92.0 93.0 - 98.8 98.4 96.5 96.3 95.4 96.6 95.0 95.7 96.1
IFN-α5 93.0 94.7 93.6 97.3 - 97.2 97.0 96.1 95.2 97.0 95.6 95.6 96.1
IFN-α6 89.3 90.9 91.4 98.4 95.7 - 95.2 95.0 94.3 95.0 96.3 94.7 95.6
IFN-α7 91.4 90.9 93.0 93.6 94.1 92.5 - 96.8 96.3 97.9 97.2 95.2 96.3
IFN-α8 90.9 90.9 94.1 92.5 92.0 91.4 94.1 - 99.1 95.9 94.3 97.3 95.6
IFN-α9 89.3 89.3 92.5 90.9 90.4 89.8 93.6 98.4 - 95.0 93.6 96.5 94.7
IFN-α10 91.4 90.9 94.1 94.7 95.2 93.0 96.8 92.0 90.4 - 97.2 96.3 96.3
IFN-α11 89.8 89.3 92.0 92.5 93.0 94.1 95.2 90.4 88.8 96.8 - 94.9 95.7
IFN-α12 93.0 92.5 97.3 92.5 92.0 91.4 92.0 95.2 93.6 93.6 92.0 - 95.6
IFN-α13 91.4 90.9 91.4 92.0 92.5 91.4 93.6 90.4 88.8 93.6 93.0 90.4 -
“–” same sequence. The upper line shows identities at the nucleotide level; The lower line shows identities at the amino acid level. The sequences for alignment
were from the following GenBank accession numbers: IFN-α1(MiIFN-α1, EU863613), IFN-α2 (MiIFN-α2, EU863614), IFN-α3 (MiIFN-α3, EU863615), IFN-α4 (MiIFN-α4,
EU863616), IFN-α5 (MiIFN-α5, EU863617), IFN-α6 (MiIFN-α6, EU863618), IFN-α7(MiIFN-α7, EU863619), IFN-α8 (MiIFN-α8, EU863620), IFN-α9 (MiIFN-α9, EU863621),
IFN-α10 (MiIFN-α10, EU863622), IFN-α11 (MiIFN-α11, EU863623), IFN-α12 (MiIFN-α12, EU863624), IFN-α13 (MiIFN-α13, EU091340).
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To evaluate the biological activity of MiIFN-α, we sub-
cloned 13 MiIFN-α cDNAs into a prokaryotic expression
vector pProEX HTb and induced their expression by
isopropyl-beta-D-thiogalactopyranoside (IPTG) in E. coli
BL21. Sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) analysis showed the presence of
protein bands at 19 kDa (Figure 3A), consistent with the
predicted molecular weights of MiIFN-α. Protein solu-
bility analysis showed that MiIFN-α recombinant pro-
teins were in the form of inclusion bodies. SDS-PAGE
analysis of the isolated inclusion bodies showed that 80%
of recombinant proteins were in inclusion bodies.
Western blot analysis of partially purified MiIFN-α
with an anti-6xHis antibody showed a specific band of
about 19 kDa (Figure 3B).
Antiviral activity of recombinant MiIFN-α
To examine the antiviral activity of recombinant MiIFN-αs,
we first used the WISH/ vesicular stomatitis virus (VSV)
system. Compared to the cells without virus infection,
challenge of WISH cells with 100 TCID50 VSV for 24 h
resulted in significant cell lesions. However, pretreat-
ment with 13 subtypes of MiIFN-α attenuated VSV-
induced cell lesions, with MiIFN-α2 and MiIFN-α12
demonstrating the strongest effects. Further analysis
showed that the effective antiviral concentrations of
MiIFN-α2 and MiIFN-α12 in WISH cells were 0.18 × 10 4
IU/mg and 0.3 × 10 3 IU/mg, respectively.
To confirm that the antiviral activity of recombinant
MiIFN-α is not limited to VSV, we employed the ca-
nine distemper virus (CDV)/Vero system. We selectedMiIFN-α2 and MiIFN-α12, because these two subtypes
exhibited the strongest antiviral activity against VSV.
The results showed that recombinant MiIFN-α2 and
MiIFN-α12 significantly inhibited CDV-induced cell
lesions. Further analysis showed that 0.145 μg purified
MiIFN-α2 protein and 0.28 μg purified MiIFN-α12
could suppress 100 TCID50 CDV-mediated cell lesions.
These data indicate that MiIFN-α2 exhibits the stron-
gest antiviral activity against VSV and CDV.
Discussion
The fur animal industry is expanding in the Northeast
and Western parts of China. However, the health of fur
animals has been compromised by viral infections, such
as those with CDV, Parvovirus, and Aleutian mink virus.
IFN was first recognized on the basis of its anti-viral
activity and only later shown to act primarily as an im-
munomodulator. IFN-α has been identified from differ-
ent species, but the biological activity of MiIFN-α has
not been tested until now. To determine whether
MiIFNα also exhibits antiviral activity similar to IFNs
from other species, we examined the ability of recom-
binant MiIFN-αs to inhibit the replication of VSV.
Using RT-PCR, we successfully amplified the predicted
564 bp mink IFN-α cDNA. The homologies of 13
MiIFN-α subtypes were 93.6–99.3% and 88.8–98.3% at
the nucleotide and amino acid sequence levels, respect-
ively. It is surprising that all the subtypes have the same
size, whereas size differences have been reported in
other species. In 14 pig IFN-αs, multiple sequence align-
ment revealed a C-terminal deletion of 8 residues in six
IFN-α subtypes (IFN-α1, α2, α3, α7, α10 and α11) [17].
Figure 1 Analysis of amino acid sequences of 13 MiIFN-α subtypes. Red underlining indicates the predicted signal sequence of MiIFN-αs.
Shaded areas represent the predicted cysteine residues, and boxed areas indicate potential N-glycosylation sites.
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approximately 2–50 times higher than those of the
subtypes with C-terminal deletions in WISH cells and
15–55 times higher in PK15 cells. In addition, the size of
feline IFN-α subtypes are different; feline IFN-α5 has
five additional amino acids inserted at position 139,
which are not present in the other four subtypes [18].
More than 10 different subtypes of IFN-α have been re-
ported in mice and 16 or more subtypes have beenreported to exist in humans. In mouse, the size of IFN-α
subtypes is variable. However, the size of the human IFN
subtypes is consistent. In mice injected with plasmids
encoding murine (Mu)IFN-α1, muIFN-α4 or muIFN-α9,
and subsequently challenged with murine cytomegalo-
virus (MCMV), muIFN-α1 exerted the greatest antiviral
effect. In another study, eight different human cell-
derived IFN-α subtypes were tested for their antiviral ac-
tivities. Human (Hu)IFN-α8 was found to be the most
Figure 2 Phylogenetic tree of IFN-α nucleotide sequences of
several animal species.
Zhang et al. BMC Veterinary Research  (2015) 11:42 Page 5 of 8potent, whereas HuIFN-α1 exhibited the least antiviral ac-
tivity. In the current study, we compared the antiviral ef-
fects of the MiIFN-α subtypes. There is no evidence to
prove that the strength of antiviral activity is related to the
size of the IFN-α subtype. Phylogenetic analysis (Figure 2)
further indicated that IFN-α was subdivided into two
monophyletic lineages: chicken (avian) and mammalian.
The mammalian branch can be divided into carnivores
and herbivores. The similarity of mink, domestic ferret,
Eurasian badger, giant panda, dog, fox, and cat IFN-αs is
consistent with their grouping within the carnivore mono-
phyletic group (which is distinct from other herbivores
IFN-αs). Indeed, both gene conversion and gene duplica-
tion have shaped the evolution of the IFN-α gene family
in eutherian species [19]. The features of MiIFN-α subtype
sequences provide more support for this view.
IFN has a broad-spectrum of antiviral effects and rep-
resents an ideal choice for the development of antiviralFigure 3 SDS-PAGE analysis of recombinant MiIFN-αs expressed in E. co
MiIFN-αs by 6-poly histidine monoclonal antibodies (B).drugs. IFN was the first cytokine approved by the US
Food and Drug Administration for clinical application.
Among the members of the IFN family, IFN-α has rela-
tively higher antiviral activity. IFN-α has been identified
from different species, including birds, rodents, and pri-
mates [20]. IFN-α is a multi-gene family, with each
member located on the same chromosome within a cer-
tain region [19]. One unique characteristic of the IFN-α
gene is that it has only one open reading frame (ORF)
without any introns. For example, dog has 8 IFN-α
genes, cat has 5 IFN-α genes, giant panda has 12 IFN-α
genes, and the marmot has 10 IFN-α genes. For each
subtype of IFN-α gene of the same species, the sequence
of the PCR product is the same whether using genomic
DNA or cDNA as the template. In this study, we cloned
13 MiIFN-α genes, including six functional genes and
two pseudogenes. In vitro assays showed that only the
product of the functional IFN gene had antiviral activity.
The reason for the genetic diversity of IFN-α during
evolution is still unclear, but different subtypes have dis-
tinct biological activities [18]. Tan et al. cloned 12 IFN-α
genes from the giant panda and found that IFN-α8, IFN-
α4, and IFN-α10 had higher activity whereas IFN-α11
had low biological activity in 293 cells (human renal epi-
thelial cells transfected with adenovirus E1A gene) [17].
Furthermore, IFN-α3, IFN-α4, and IFN-α8 demonstrated
higher activity in B6 cells, whereas IFN-α3, IFN-α7, and
IFN-α10 showed higher activity in K562 cells [18]. Taira
et al. cloned 5 dog IFN-α genes and found that rCaIFN-
α8 demonstrated high anti-VSV activity. In addition, the
anti- canine adenovirus (CAV)-1 activity of rCaIFN-α8
in Madin-Darby canine kidney (MDCK) cells was 33–666
times higher than the anti-VSV activity, but rCaIFN-α8
had no effects on CHV-1 [21]. Taken together, these data
suggest that IFN-α has many subtypes, most of which
have antiviral activity in different types of cells. Although
the IFN-α family has many pseudogenes that can be tran-
scribed into mRNA, these pseudogenes have no anti-viral
function. The potential roles of the pseudogenes of IFN-α
remain to be determined.li induced by IPTG (A). Western blot analysis of His-tag recombinant
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ant role during the immune response to viral infection.
IFN-α is a multi-gene family consisting of different sub-
types with high homology and similar function. How-
ever, recent studies have demonstrated that there are
functional differences among the subtypes, probably due
to the different amino acid sequences. Indeed, our 13
cloned MiIFN-αs demonstrated a variety of constituent
amino acids in each subtype. MiIFN-α4–13 had two N-
glycosylation sites, whereas MiIFN-α1–3 had only one
N-glycosylation site. IFN-α1–3, IFN-α5, IFN-α7, IFN-
α10, IFN-α11, and IFN-α13 had 9 cysteine residues,
whereas IFN-α4, IFN-α6, IFN-α8, IFN-α9, and IFN-α12
contained only 8 cysteine residues. Antiviral activity ana-
lysis showed that only IFN-α1, IFN-α2, IFN-α3, IFN-α8,
IFN-α9, and IFN-α12 had antiviral function. It will be in-
teresting to investigate whether N-glycoslylation sites are
essential for the antiviral activity of IFN-α.Conclusions
In summary, in this study for the first time, we have
cloned 13 subtypes of the MiIFN-α gene and successfully
expressed them in E. coli. Most of the purified recombin-
ant MiIFN-α subtypes demonstrated antiviral activity
against VSV and CDV, and MiIFN-α2 exhibited the high-
est antiviral activity. Therefore, the MiIFN-α2 subtype is a
promising candidate for the development of effective anti-
viral drugs for the fur animal industry.Methods
Reagents
VSV was provided by Dr. Haidong Zhi from the Institute
of Harbin Veterinary Research, Chinese Academy of
Agricultural Sciences (CAAS). Canine distemper virus
(CDV) strains were from commercial CDV-3 vaccine
strains. WISH and Vero cells were purchased from the
Chinese Academy of Sciences Shanghai Cell Bank. Plas-
mid pProEX HTb, E. coli JM109/BL21, and TRIzol were
purchased Invitrogen (USA). RPMI 1640 medium was
purchased from GIBCO. Lymphocyte isolation reagent
was from the Chinese Academy of Medical Sciences.
ExTaq polymerase, AMV reverse transcriptase, and Con-
canavalin A (Con A) were purchased from Sigma (USA).
The Ni-NTA protein purification system and anti-6xHis
monoclonal antibodies were purchased from Invitrogen.Table 3 Primers used in MiIFN-α and mature peptide (mMiIFN
Gene fragment Predicted size (bp)
MiIFN-α1–13 564
mMiIFN-α1–13 495PCR primers were synthesized by Shanghai Ying-Jun
Biotech.
Six-month-old minks were purchased from a fur ani-
mal farm in the Jilin Province of China and housed in
boxes at the animal house of the Central Laboratory for
Animal Diseases of the Institute of Special Animal and
Plant Sciences. All animal work and experimental proce-
dures were performed according to the regulations for
the administration of affairs concerning experiental ani-
mals, which was approved by the state council on October
21, 1988 and promulgated by decree No. 2 of the State
Science and Technology Commission on November 14,
1988.RT-PCR and analysis of IFN-α sequences
Peripheral blood lymphocytes (PBMCs) were separated
under sterile conditions from healthy minks, stimulated
with 25 μg/mL ConA for 24 h, centrifuged, and resus-
pended in 1 mL TRIzol reagent. Total RNA was isolated
by the phenol/chloroform method as described previ-
ously [22,23]. cDNA was synthesized from total RNA
using Oligod (T)15 primer, and PCR was performed with
cDNA and primers to amplify IFN-α cDNA [16]. The
primer sequences are shown in Table 3. The PCR prod-
ucts were subcloned into the pGEM-T vector for
sequencing at Shanghai Ying-Jun BioTech (Invitrogen).
The amino acid sequences of the MiIFN-αs ORF were
aligned with that of IFN-αs of arctic fox, raccoon, and
dog IFN-α from GenBank using DNAStar 5.0 software.
A multi-species phylogenetic tree based on the nucleo-
tide sequences of the various IFNs was constructed with
DNAStar 5.0 MegAlign software. Signal peptides were
predicted using online SignalP 4.1 server (http://www.cbs.
dtu.dk/Services/SignalP/). The glycosylation sites were
predicted using the online 1.0 NetNGlyc Server.Construction of mMiIFN-α1–13 expression vector
The PCR products were separated by 1.5% agarose gel
electrophoresis. The gel purified DNA was cut with
BamH I and Hind III, ligated into the pProEX HTb
vector, and transformed into competent E. coli /BL 21
cells. Positive clones were validated by PCR and restric-
tion enzymes digestion and sequenced by Shanghai
Ying-Jun BioTech. The recombinant plasmid was named
pHTb/MiIFN-α.-α) gene PCR assays
Primers Tm(°C)
P1 5′-ATGGCCCTGCCCTGCTCCT- 3′ 50.1
P2 5′-TCACTTCCTGCTCCGCAATC-3′
P3 5′- CGGGATCCTGTGACCTGCCTCAG-3′ 55
P4 5′- CCAAGCTTTCACTTCCTGCTCCGCAAT-3′
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pHTb/MiIFN-αs were transformed into E. coli BL21 com-
petent cells and selected with ampicillin. Positive clones
were inoculated in 5 ml liquid Luria broth (LB) media and
cultured at 37°C. When the optical density at 600 nm
(OD600) reached 0.5, 1 mmol/L IPTG was added to induce
protein expression. For purification, the bacteria were cen-
trifuged at 10,000 rpm for 10 min. Following several cycles
of freezing and thawing, the bacterial pellet was mixed
with 1 mg/mL lysozme and lysed by sonication on ice.
After collection by centrifuging at 4°C at 10,000 rpm for
10 min, the pellet was washed with buffer (1% Triton X-
100, 50 mmol/ml Tris · HCl pH 8.0, 100 mmol/mL NaCl)
and dissolved in 8 mol/L urea buffer. Then 50% NI –NTA
(4:1) was added and incubated on ice with slow mixing
using a magnetic stirrer blender. Finally, the mixture was
loaded onto a chromatography column (Novagen) and
eluted by serial washing (using pH 8.0, pH 6.3, and pH 4.5
50 Mm Tris · HCl buffer containing 8 M urea). The elu-
ents were separated by 12% SDS-PAGE and transferred
onto a PVDF membrane. The membrane was blocked
with 5% milk in TBST (0.1 phosphate buffer contain 0.5%
Tween20) and incubated with mouse anti-6xHis monoclo-
nal antibody (1:300) at 4°C overnight, followed by incuba-
tion with goat anti-mouse IgG-HRP (1:2000) at room
temperature for 1 h. Finally, the membrane was developed
using the TMB Chromogenic Reagent (Sigma, USA).
Antiviral activity assay
The antiviral activity of 0.5 mg/mL recombinant IFN-α
was determined by cytopathic inhibition assay. WISH
cells were plated in 96-well plates and incubated at 37°C
with 5% CO2 for 12–18 h. Diluted recombinant IFN-α
was added to the cell monolayer and incubated at 37°C
with 5% CO2 overnight. Next, the cells were challenged
with 100 TCID50 VSV, and the plates were incubated at
37°C for 1–2 days. VSV-induced cytopathic effects were
assessed by microscopic examination, and IFN-α con-
centrations were expressed as the inverse dilution that
provided protection of 50% of the cells from VSV-
induced cytopathic effects (CPE50).
In addition, the antiviral activity of recombinant IFN-α
was determined by the inhibition of CDV propagation in
Vero cells. The titer of CDV TCID 50 was determined by
reference for Reed-Muench method. Vero cells were plated
in 24-well plates until the formation of a monolayer. Di-
luted recombinant IFN-α was added to the cell monolayer
and incubated at 37°C with 5% CO2 overnight. Next, the
cells were challenged with 100 TCID50 CDV, and the plates
were incubated at 37°C for 1–2 days. The CDV-induced cy-
topathic effects were assessed by microscopic examination,
and IFN-α concentrations were expressed as the inverse di-
lution that provided protection of 50% of the cells from
CDV-induced cytopathic effects (CPE50).Competing interest
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